Journey Medical Q1 revenue rises, adjusted EBITDA turns positive

Journey Medical

13/05/2026 21:14

Overview

US dermatology drugmaker's Q1 revenue rose 21%, slightly beating analyst expectations

Net loss narrowed to $2.2 mln, while adjusted EBITDA turned positive

Gross margin fell due to a non-recurring inventory write-down

Outlook

Company expects improved operating leverage to continue throughout the year

Expanded payer access anticipated to drive further growth in Emrosi(®) prescription demand

Company says it is well-positioned to execute its strategy and deliver financial progress in 2026

Result Drivers

EMROSI SALES GROWTH - Revenue increase driven by Emrosi, which generated $6.3 mln in Q1, up from $2.1 mln a year earlier

PRESCRIPTION DEMAND & PAYER COVERAGE - Co cited rising prescription demand, expanded payer coverage, and higher refill rates for Emrosi as supporting growth

LOWER LAUNCH COSTS - Decrease in selling, general and administrative expenses attributed to lower Emrosi launch costs versus prior year

Company press release: ID:nGNX77mpXJ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Beat*
$16 mln
$15.95 mln (4 Analysts)
Q1 EPS
-$0.08
Q1 Net Income
-$2.20 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Journey Medical Corp is $13.00, about 159.5% above its May 12 closing price of $5.01

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 33 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)